Myocarditis: clinical presentation

ESC CardioMed ◽  
2018 ◽  
pp. 1515-1521
Author(s):  
Alida L. P Caforio ◽  
Renzo Marcolongo ◽  
Sabino Iliceto

Myocarditis has no typical clinical presentation, and may mimic a variety of non-inflammatory myocardial diseases. Cardiac signs and symptoms lack specificity, depending on the degree of myocardial inflammation and ventricular dysfunction, and may be subtle; thus the disease may be unrecognized. Myocarditis may resolve spontaneously, recur, or become chronic leading to dilated cardiomyopathy, sudden or heart failure-related death, or heart transplantation. In 2013, a European Society of Cardiology (ESC) Myocarditis Task Force proposed new criteria for clinically suspected myocarditis, using the combination of a plausible clinical presentation and diagnostic criteria. Importantly, diagnosis requires exclusion of non-inflammatory disease (e.g. coronary artery disease) that could explain specific presentations. The ESC 2013 Task Force also recommended a systematic consideration of endomyocardial biopsy in clinically suspected myocarditis, provided that endomyocardial biopsy includes standard histology, immunohistochemistry, and molecular analysis for infectious agents.

ESC CardioMed ◽  
2018 ◽  
pp. 1515-1521
Author(s):  
Alida L. P Caforio ◽  
Renzo Marcolongo ◽  
Sabino Iliceto

Myocarditis has no typical clinical presentation, and may mimic a variety of non-inflammatory myocardial diseases. Cardiac signs and symptoms lack specificity, depending on the degree of myocardial inflammation and ventricular dysfunction, and may be subtle; thus the disease may be unrecognized. Myocarditis may resolve spontaneously, recur, or become chronic leading to dilated cardiomyopathy, sudden or heart failure-related death, or heart transplantation. In 2013, a European Society of Cardiology (ESC) Myocarditis Task Force proposed new criteria for clinically suspected myocarditis, using the combination of a plausible clinical presentation and diagnostic criteria. Importantly, diagnosis requires exclusion of non-inflammatory disease (e.g. coronary artery disease) that could explain specific presentations. The ESC 2013 Task Force also recommended a systematic consideration of endomyocardial biopsy in clinically suspected myocarditis, provided that endomyocardial biopsy includes standard histology, immunohistochemistry, and molecular analysis for infectious agents.


Author(s):  
Ilaria Spoletini ◽  
Petar Seferovic

Co-morbidities are particularly relevant in the management of HF as they may confound HF diagnosis, worsen symptomatology, impact quality of life and aggravate the prognosis. According to the most recent European Society of Cardiology (ESC) guidelines, treatment of co- morbidities is an essential element of the comprehensive care of HF. Angina and coronary artery disease (CAD), in particular are common disorders associated with HF. The pharmacological and surgical management of angina according to the ESC guidelines is reviewed in this article.


Sign in / Sign up

Export Citation Format

Share Document